Abstract | PURPOSE: PATIENTS AND METHODS: In post hoc exploratory analyses from CheckMate 032 (GC/GEJC cohort), we evaluated associations between nivolumab ± ipilimumab (NIVO ± IPI) efficacy and programmed death ligand 1 (PD-L1) expression, defined by tumor cells (% TC) or combined positive score (CPS; sum of PD-L1-staining TCs + immune cells, divided by total viable TCs, × 100) using the Dako PD-L1 IHC 28-8 pharmDx assay, or inflammatory gene expression. RESULTS: There was a trend toward increased efficacy (objective response and overall survival) when PD-L1 expression was determined by CPS compared with % TC at higher cutoffs of ≥5 and ≥10 in the pooled analysis of all treatment regimens. In this analysis, 19% and 26% of patients with PD-L1-positive tumors at a CPS cutoff of ≥5 and ≥10, respectively, had an objective response compared with 8% and 9% of patients at the equivalent % TC cutoffs. Longer survival was demonstrated in patients with PD-L1-positive (defined by CPS cutoffs of ≥5 and ≥10) versus PD-L1-negative status. Similar results were observed in the NIVO 1 mg/kg + IPI 3 mg/kg subgroup. Multiple inflammatory gene signatures/transcripts, including a signature consisting of four genes (CD274, CD8A, LAG3, and STAT1), showed associations with response to NIVO ± IPI. CONCLUSIONS: This study suggests a greater association of PD-L1 expression by CPS with NIVO ± IPI efficacy compared with % TC PD-L1 expression in patients with GC/GEJC. Inflammatory signatures were also associated with NIVO ± IPI response, warranting further investigation.See related commentary by Moutafi and Rimm, p. 3812.
|
Authors | Ming Lei, Nathan O Siemers, Dimple Pandya, Han Chang, Teresa Sanchez, Christopher Harbison, Peter M Szabo, Yelena Janjigian, Patrick A Ott, Padmanee Sharma, Johanna Bendell, Thomas R Jeffry Evans, Filippo de Braud, Ian Chau, Zachary Boyd |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 27
Issue 14
Pg. 3926-3935
(07 15 2021)
ISSN: 1557-3265 [Electronic] United States |
PMID | 33782030
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | ©2021 American Association for Cancer Research. |
Chemical References |
- Antineoplastic Agents, Immunological
- B7-H1 Antigen
- CD274 protein, human
- Ipilimumab
- Nivolumab
|
Topics |
- Aged
- Antineoplastic Agents, Immunological
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- B7-H1 Antigen
(genetics)
- Esophageal Neoplasms
(complications, drug therapy, genetics)
- Esophagogastric Junction
- Female
- Humans
- Inflammation
(complications, genetics)
- Ipilimumab
(administration & dosage)
- Male
- Middle Aged
- Nivolumab
(administration & dosage)
- Stomach Neoplasms
(complications, drug therapy, genetics)
- Treatment Outcome
|